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Abstract. 
 
Upon antigen contact, epidermal Langer-
hans cells (LC) and dendritic cells (DC) leave periph-
eral organs and home to lymph nodes via the afferent 
lymphatic vessels and then assemble in the paracortical 
T cell zone and present antigen to T lymphocytes. Since 
splice variants of CD44 promote metastasis of certain 
tumors to lymph nodes, we explored the expression of 
CD44 proteins on migrating LC and DC. We show that 
upon antigen contact, LC and DC upregulate pan 
CD44 epitopes and epitopes encoded by variant exons 
v4, v5, v6, and v9. Antibodies against CD44 epitopes in-
hibit the emigration of LC from the epidermis, prevent 
binding of activated LC and DC to the T cell zones of 
lymph nodes, and severely inhibit their capacity to in-
duce a delayed type hypersensitivity reaction to a skin 
hapten in vivo. Our results demonstrate that CD44 
splice variant expression is obligatory for the migration 
and function of LC and DC.
 
E
 
pidermal 
 
Langerhans cells (LC)
 
1
 
 belong to the den-
dritic cell (DC) family and are potent antigen-pre-
senting cells located in the suprabasal layers of the
epidermis (3, 30, 36). After antigen uptake, LC leave the
epidermis and migrate into dermis, where they travel via
afferent lymphatics into the regional lymph nodes to present
antigen to T cells (9, 26). The mechanisms that govern
their migration, entry, and movement in lymphatic vessels
and subsequent homing and adhesion to distinct areas
within secondary lymphatic tissues remain unidentified.
CD44 is a heterogeneous multifunctional molecule ex-
pressed by cells of different origin including immunocom-
petent cells (15). CD44 is encoded by a total of 20 exons,
seven of which form the invariant extracellular region of
the so-called standard form (CD44s). By alternative splic-
ing, up to 10 variant exons (CD44v1–v10) can be inserted
within this invariant extracellular region (37). In humans,
exon v1 seems to be nonfunctional because of a stop
codon (17). CD44 is involved in a variety of cellular func-
tions. Among them are lymphocyte homing to skin and to
lymph nodes (23, 33), lymphopoesis (29), and lymphocyte
activation (10, 20, 39). As a major cell surface receptor for
the extracellular matrix (ECM)-component hyaluronate
(HA), CD44 has been shown to regulate cell migration on
HA-coated substrates (2, 48, 49). Furthermore, CD44 iso-
forms containing variant exon v6 play a crucial role during
the early phases of metastasis of rat pancreatic adenocarci-
noma cells to peripheral lymph nodes (LN) (14, 38).
Taken together, these findings suggest that CD44 is of cen-
tral importance for physiological or pathological cell mi-
gration and cell adhesion to lymphatic tissues.
It remains unknown which CD44 isoforms are expressed
on LC and which functional properties are attributed to
their expression. In this study we show that CD44 isoforms
are differentially modulated during the activation and mi-
gration of LC, and participate in their migration out of
skin, their adhesion to the paracortical T cell zones of pe-
ripheral LN, and the LC-dependent sensitization phase of
contact hypersensitivity.
 
Materials and Methods
 
Media and Chemicals
 
Complete-RPMI 1640 (c-RPMI) (Gibco, Eggenstein, Germany) was sup-
plemented with 10% heat inactivated FCS (Gibco), 25 mM Hepes (Sigma
Chemical Co., München, Germany), 1 mM nonessential amino acids
 
(Gibco), 2 mM 
 
l
 
-glutamine (Gibco), 1 nM 2-mercaptoethanol (Sigma
Chemical Co.), 4 
 
m
 
g penicillin, and 45 
 
m
 
g streptomycin (Gibco). Minimal
essential medium (MEM) (Gibco) was supplemented with 1.3 U/ml
DNAse I (Boehringer Mannheim, Ingelheim, Germany), 10% FCS, 45 
 
m
 
g
penicillin, and 45 
 
m
 
g streptomycin (both from Gibco). Organ culture me-
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dium comprised 75% DME, 25% HAMS-F12, 45 
 
m
 
g penicillin, 45 
 
m
 
g
streptomycin, 10% FCS (all from Gibco).
 
LC and DC Isolation
 
Epidermal cell suspensions were generated by limited trypsinization of
human skin obtained during plastic surgery (51), and from trunk skin of
female C57/BL6 mice (40) (Harlan Winkelmann, Boechen, Germany). LC
were enriched by density gradient centrifugation on Lymphoprep (Gibco)
to 5–20% LC. Both fresh LC and LC cultured in supplemented RPMI for
48 or 72 h were analyzed by FACS
 
®
 
. Human DC were generated as de-
scribed (35) yielding 80–90% CD1a
 
1
 
 cells. Murine DC were generated
from C57/BL6 bone marrow as described (21).
 
GST Fusion Proteins
 
DNA fragments encoding combinations of murine CD44v exons were am-
plified by PCR with primers based on the murine CD44 variant sequence
(49a), using cDNA synthesized from mRNA made from KLN205 cells
(CRL 1453; American Type Culture Collection, Rockville, MD) as a tem-
plate. These DNA fragments were cloned into pGEX vectors (43a) to cre-
ate plasmids encoding GST–CD44v fusion proteins. The plasmids were in-
troduced into DH5-
 
a
 
 bacteria and GST–CD44v fusion protein was
induced and purified as previously described (43a).
 
Antimurine CD44v Monoclonal Antibodies
 
Female DA rats were immunized with GST-CD44v4-v10 or v6–v7 fusion
proteins. Hybridomas were made by using the 30% PEG spinning method
(14a) to fuse SP2/0 myeloma cells to immune rat spleen cells. Hybridomas
were screened for secretion of murine CD44v-specific antibodies by using
the immunogen as the immobilized target in ELISA assays, in which rab-
bit anti–mouse antibodies coupled to horseradish peroxidase were used as
the second antibody, and 2,2
 
9
 
-azino-bis(3-ethylbenz-thiazoline-6-sulfonic
acid) diammonium salt (ABTS; Sigma Chemical Co.) was used to detect
antibody binding (14a). Secreted antibodies were further screened for
their ability to bind to histological sections of normal murine tissue known
to express CD44 variants, such as skin. The murine CD44v exon-encoded
sequences recognized by positively reacting antibodies were mapped us-
ing ELISA assays. These ELISAs used fusion proteins consisting of GST
fused to defined murine CD44 variant exon-encoded sequences as immo-
bilized targets. In this way, the positively reacting antibodies 9A4 and
10D1 were shown to recognize sequences encoded by exons v6 and v4 of
murine CD44, respectively. The isotypes of 9A4 and 10D1 (both IgG
 
1
 
,
kappa) were determined using an Isostrip™ kit (Boehringer Mannheim
Corp.). Purified 9A4 and 10D1 antibodies were prepared from condi-
tioned medium as described (14a) using protein G–agarose (Dianova) as
the affinity column.
 
Immunostaining and Flow Cytometry
 
Cells were stained as described (51) with one of the following mAbs: (
 
a
 
)
human-specific pan CD44 mAbs (recognizing the NH
 
2
 
-terminal epitope
of CD44), Leu 44 (clone L178, mouse IgG1; Becton Dickinson, Heidel-
berg, Germany); mAb MEM-85 (pan CD44, mouse IgG1, Monosan,
Uden, The Netherlands); exon v4, 11.10 (mouse IgG1, ECACC); exon v5,
VFF8 (mouse IgG1; Bender GmbH, Vienna, Austria); exon v6, VFF18
(mouse IgG1; Bender GmbH); exon v7/v8, VFF17 (mouse IgG2b; Bender
GmbH); exon v9, 11.24 (mouse IgG1, ECACC); (
 
b
 
) murine specific: NH
 
2
 
-
terminal epitope 
 
5
 
 pan CD44, IM7 (rat IgG2b, American Type Culture
Collection, Rockville, MD); exon v4, 10D1 (rat IgG1); exon v6, 9A4 (rat
IgG1); isotype control, IB7 (rat IgG1; Dianova, Hamburg, Germany).
Secondary antibodies: FITC-labeled goat anti–mouse (Fab)
 
2
 
 and goat
anti–rat (Fab)
 
2
 
 (Dianova). Treatment with secondary antibody was fol-
lowed by a 10-min incubation in 2% normal murine or rat serum, and sub-
sequently by incubation with PE-labeled HLA-DR–specific mAb (L234,
mouse IgG1; Becton Dickinson) or Ia
 
b
 
 (mouse IgG2b; PharMingen, Ham-
burg, Germany) or appropriate nonreactive PE-labeled control Ab (Di-
anova). Human DC were identified by FITC-conjugated mAb against
CD1a (Okt-6, mouse IgG1, Ortho). 7-Aminoactinomycin D (2.5 
 
m
 
g/ml;
Sigma) was added to exclude dead cells by appropriate gating. Cell Quest
software (Becton Dickinson) was applied to analyze 10
 
4
 
 HLA-DR
 
1
 
,
CD1a
 
1
 
, or Ia
 
b
 
1
 
 viable cells each and to calculate mean fluorescence in-
tensity.
 
Electron Microscopy
 
Skin specimen cultured for time periods mentioned were fixed for 12 h at
4
 
8
 
C in 3% cacodylate-buffered glutaraldehyde at pH 7.4 and then trans-
ferred to a 5% sucrose solution. Postfixation was performed with 1% os-
mium tetroxide and potassium ferricyanide. The specimens were washed
with distilled water, dehydrated in graded alcohols, and embedded in
araldit resin. Ultrathin sections of 50 nm were cut, placed on copper grids,
stained with uranyl acetate and lead citrate, and examined on an electron
microscope (model CM10; Philips, Eindhoven, The Netherlands) at 80 kV.
 
Full-Thickness Skin Organ Culture
 
4-mm punch biopsies containing dermis and epidermis were placed into 25-
mm tissue culture inserts with a 0.02-
 
m
 
m anopore membrane (Nunc Inc.,
Naperville, IL) and incubated in six-well tissue culture plates filled with
supplemented DME/HAMS-F12 up to the dermal–epidermal junction.
Cultures were terminated as indicated, and samples were shock-frozen in
N
 
2
 
. Immunofluorescence double labeling was performed as described pre-
viously (32, 41). Sections (5 
 
m
 
m) were prepared with a Cryocut 1800 (Leica,
Benzheim, Germany). First, sections were incubated with Lag mAb for 30
min (room temperature) followed by FITC-conjugated F(ab), goat anti–
mouse IgG (H
 
1
 
L) (Dianova) overnight at 4
 
8
 
C. In a second step, sections
were overlaid with mAb against CD44v (Leu44, MEM-85, VFF8, VFF18,
VFF17, 11.24) for 30 min (room temperature), followed by a Cy3-conju-
gated goat F(ab)
 
2
 
 anti–mouse IgG (H
 
1
 
L) antibody for 4 h at 4
 
8
 
C. The fol-
lowing controls were performed: As control for type II interference (bind-
ing of the second step anti–mouse Ab to the mouse Ab of the first step),
sections were stained with first step murine mAb, followed by unconju-
gated F(ab) goat anti–mouse IgG (H
 
1
 
L) (Dianova). Subsequently, sec-
tions were overlaid with Cy3-conjugated goat F(ab)
 
2
 
 anti–mouse IgG
(H
 
1
 
L), revealing no staining at incubation times indicated above. Stain-
ing was evaluated with a microscope (model Axioskop; Carl Zeiss, Inc.,
Göttingen, Germany), equipped with a MC100 camera system. For quan-
titative analysis of total and CD44
 
1
 
/Lag
 
1
 
 double-positive LC, five high-
power fields were counted and LC/mm
 
2
 
 was quantified as mentioned in
the text.
 
Split Thickness Organ Culture
 
2 
 
3
 
 2-cm split thickness skin containing epidermis plus papillary dermis
was prepared by dermatome (Aesculap, Tuttlingen, Germany) (34) and
floated on supplemented RPMI in six-well plates (Greiner). After 48 h,
cells that had migrated into the culture medium were collected. Staining
with FITC-conjugated mAbs against CD1a and FACS
 
®
 
 was performed as
described above. All cells obtained from one well (5–6 
 
3
 
 10
 
5
 
) were ana-
lyzed. The percentage of CD1a
 
1
 
 cells was calculated by Cell Quest soft-
ware (Becton Dickinson). The percentage of emigrating LC from un-
treated samples was defined as 0% inhibition.
 
Lymph Node Adhesion Assay
 
LC or DC enriched by MACS (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) (43) with antibodies to HLA-DR or CD1a, were tested for frozen-
section lymph node adhesion as described (7). 10-
 
m
 
m fresh cryosections of
human axillary lymph nodes were mounted on glass slides and blocked
with RPMI containing 1% BSA (7
 
8
 
C, 1 h). LC or DC were suspended in
HBSS/1% BSA (2 
 
3
 
 10
 
6
 
/ml) and layered over the cryosections at room
temperature (40 min). Slides were gently rinsed with HBSS and then fixed
in acetone (4
 
8
 
C, 10 min). For antibody blocking, LC or DC were preincu-
bated with mAbs MEM-85 (pan CD44, mouse IgG1), SFF-2 (pan CD44,
mouse IgG1), with v exon–specific antibodies (v5, VFF-8; v6, VFF-18; v9,
11.24), ICAM-1 mAb 84H10 (anti–ICAM-1, mouse IgG1; Immunotech,
Hamburg, Germany), RR1 (anti–ICAM-1, mouse IgG1, kind gift of Dr.
T.A. Springer, Harvard Medical School, Boston, MA) or control IgG1 (20
 
m
 
g/ml, 30 min, 4
 
8
 
C). The slides were then stained with anti-CD1a mAb
and coded and evaluated by two independent investigators. Background
binding of cultured LC/DC did not exceed 1.5 cells/mm
 
2
 
, and positive
binding was 
 
.
 
30 cells/mm
 
2
 
. Data are presented as percent binding com-
pared to samples without antibodies. SD was calculated from three slides
each with nine random fields/slide using an optical grid (10
 
3
 
 magnifica-
tion).
 
Contact Hypersensitivity
 
6-wk-old female C57/BL6 mice (Harlan Winkelmann) were painted on 
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their abdominal skin with 20 
 
m
 
l 0.5% 2,4-dinitro-1-fluorobenzene (DNFB;
Sigma Chemical Co.) in acetone at days 0 and 1 (42). On day 6, mice were
challenged by painting 10 
 
m
 
l 0.2% DNFB on both sides of the right ear.
Ear thickness was measured with an engineer’s micrometer (Mitutoyo
GmbH, Neuss, Germany) before and at 24, 48, and 72 h after the chal-
lenge (42). For histology, ears were excised 24 h after challenge, fixed in
formaldehyde, paraffin-embedded, sectioned, and counter-stained with
hematoxylin and eosin. Photographs were taken with a camera system
(model MC100; Olympus, Hamburg, Germany). Group 1 mice were ei-
ther challenged only or sensitized and challenged in the absence of mAbs.
Injection of mAbs (i.p.) was performed as follows: Group 2 mice received
300 
 
m
 
g at day 
 
2
 
1, 100 
 
m
 
g each at days 0 and 1, with respect to hapten ap-
plication during sensitization. Group 3 mice received 300 
 
m
 
g at day 5 and
100 
 
m
 
g each at days 6 and 7.
 
Results
 
In Vitro–activated LC and DC Upregulate pan CD44 
and CD44 Variant Isoforms
 
To determine whether LC express CD44 and whether this
expression is altered by activation, we transferred LC
freshly isolated from human epidermis into tissue culture.
This procedure mimics LC activation by antigen in vivo
(36). Cells were stained with mAbs against HLA-DR to
identify LC and with mAbs against CD44 epitopes. HLA-
DR
 
1
 
 freshly isolated LC expressed an NH
 
2
 
-terminal
Figure 1. Change in CD44 epitope expression during in vitro cultivation of epidermal LC and blood DC. (A) Human LC freshly isolated
and after 48 and 72 h of culture and (C) mouse DC generated from C57/BL6 bone marrow were stained with mAbs against HLA-DR or
Iab, 7-aminoactinomycin-D, and mAbs directed against CD44 epitopes. Mean fluorescence intensity of viable and HLA-DR1 cells was
determined by FACScan® and is shown in the upper right corner of each graph. Data is representative for six independent experiments.
Low expression of CD44v epitopes on freshly isolated LC was not caused by the trypsinization used during the isolation procedure,
since identical trypsinization of cultured LC did not affect their CD44v expression significantly (not shown). (B) Corresponding analysis
of DC generated from human peripheral blood monocytes gated for CD1a. Data is representative for four independent experiments. 
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epitope of CD44 (termed pan CD44) and an epitope
formed jointly by CD44 exons v7 and v8 (Fig. 1 
 
A
 
).
Epitopes encoded by exons v5 and v6 were only weakly
expressed, while epitopes encoded by exons v4, v9, and
v10 were not detectable (Fig. 1 
 
A
 
 and data not shown). LC
cultured for 48 and 72 h carried enhanced levels (twofold)
of the NH
 
2
 
-terminal epitope. The epitopes of v4, v5, v6,
and v9 were also markedly upregulated (Fig. 1 
 
A
 
 and not
shown). In contrast, the CD44v7/8 epitope was lost during
culture (Fig. 1 
 
A
 
). A CD44v10 epitope was not detectable
(data not shown).
LC belong to the family of dendritic cells (45). To deter-
mine whether DC from other sources express similar
CD44 isoforms as LC, DC were prepared from human pe-
ripheral blood by culture in a cytokine cocktail (35). De-
termination of CD44 isoforms on DC revealed strong ex-
pression of panCD44 (Fig. 1 
 
B
 
) and epitopes of CD44v5,
v6, and v9 (Fig. 1 
 
B
 
), whereas the v7/8 epitope was not de-
tected (Fig. 1 
 
B
 
). Our data thus revealed CD44 epitope
patterns identical to those on cultured LC. A very similar
CD44 pattern also occurred in cultured LC and DC from
C57/Bl6 murine skin or bone marrow with expression of
pan CD44 epitopes and epitopes encoded by CD44v4 and
v6 (Fig. 1 
 
C
 
 and not shown).
 
CD44 Isoform Expression on Migrating LC
 
To explore at what stage LC acquire altered expression of
CD44 epitopes during migration, we made use of a skin
explant culture in which LC move actively from epidermis
into dermis. The migration of LC was assessed by quanti-
fying the number of Lag
 
1
 
 cells (mAb Lag stains Birbeck
granules, specific cytoplasmic organelles of LC [24])
within epidermis and dermis after various culture intervals
of skin explants. At 0 h, almost all Lag
 
1
 
 cells were located
in the suprabasal layers of the epidermis with very few
Lag
 
1
 
 cells detectable in the dermis. After 72 h of culture,
almost half of the LC had left the epidermis, which, how-
ever, was never depleted completely of LC (Table I). This
LC emigration was further investigated at the ultrastruc-
tural level by transmission EM (Fig. 2). As early as 2 h af-
ter culture, epidermal LC, identified by their characteristic
intracytoplasmic Birbeck granules, had started their mi-
gration (Fig. 2, 
 
A
 
 and 
 
B
 
) and at 12 h were found to pene-
trate the basement membrane of the epidermo–dermal
junction. After 24 h, LC accumulated in the dermis in
cordlike structures within lymphatic vessels (Fig. 2, 
 
C
 
 and 
 
D
 
).
By immunohistochemical double labeling with mAb
Lag (FITC, green) and CD44-specific mAbs (Cy3, red),
we followed CD44 expression on LC during migration.
Double staining appears as yellow. Keratinocytes stained
red since they carry several CD44 epitopes (CD44v3–v10)
(18, 19) but not the Lag epitope. Most intraepidermal LC
expressed NH
 
2
 
-terminal epitopes and the epitope encoded
by v7/8, whereas only few (
 
<
 
5%) of them showed staining
with antibodies to epitopes encoded by exons v5, v6, or v9
(Fig. 3, 
 
A–C
 
, 
 
E
 
, and 
 
G
 
). In contrast, the majority of LC
that had migrated into the dermis (87.5–100%) expressed
v5, v6, and v9 epitopes (Fig. 3, 
 
D
 
, 
 
F
 
, and 
 
H
 
). Thus, the
change in epitope presentation apparently occurs with the
transition from epidermis to dermis.
These findings were confirmed and extended using the
method described by Pope et al. (34) to examine LC that
had migrated completely out of the skin. Split thickness
keratome skin was floated on culture medium. After 48 h,
LC were collected from the medium and their CD44 pat-
tern was analyzed by triple color FACS
 
®
 
 analysis. These
LC carried epitopes of the CD44 NH
 
2
 
 terminus, v5, v6,
and v9, but not v7/8 (Fig. 3, 
 
I
 
 and 
 
J
 
). Thus the CD44 phe-
notype of migrating LC matched exactly that of in vitro–
activated LC or DC.
To track LC migration further, we identified LC that
had traveled via lymphatic vessels to the regional lymph
nodes in cryosections of axillary lymph nodes. Lag
 
1
 
 cells
were found in the paracortical T cell zones of the lymph
node and the majority expressed the CD44 NH
 
2
 
 terminus
(Fig. 4 
 
A
 
), epitopes of exons v4, v5, v6 (Fig. 4 B and data
not shown), and v9 (Fig. 4 C), but not the v7/8 epitope (not
shown). We conclude that the CD44 expression pattern
acquired during emigration from the epidermis is main-
tained until LC have reached the lymph node.
CD44 Isoforms Serve a Functional Role in LC 
Migration Out of Skin and LC Adhesion to LN
We next used anti-CD44 mAbs to determine the func-
tional relevance of CD44 protein expression. To check for
CD44 function during LC migration, the anti-CD44 NH2-
terminal antibodies MEM-85 (blocks HA binding [6]) and
SFF2 (does not block HA binding; Weiss, J.M., C.C. Ter-
Table I. CD44v Expression on Lag1 Epidermal and Dermal Langerhans Cells after Different Culture Intervals of Full-Thickness 
Skin Explants
Epidermis Dermis
Culture
period
*Number of
Lag1 ‡CD44v51 ‡CD44v61 ‡CD44v91
*Number of
Lag1 ‡CD44v51 ‡CD44v61 ‡CD44v91
h cells/mm2 % % % cells/mm2 %%%
0 985.7 0 4.2 7.8 30.6 100 100 80.0
2 927.4 0.9 2.8 6.4 67.3 95.5 91.6 83.4
6 927.4 0 1.3 6.5 67.3 94.5 94.1 88.9
12 768.4 2.7 5.1 7.2 84.6 88.1 89.0 83.3
24 756.1 0 3.7 5.6 84.6 88.9 100 75.0
48 675.0 0.7 5.9 10.7 76.5 92.3 96.3 91.0
72 609.2 0.7 2.9 7.1 102.6 87.5 100 91.0
*Full-thickness skin organ culture and immunohistochemistry was performed as described in Fig. 3.
‡CD44v positive and negative Lag1 cells were counted in 10 high power fields and the percentage of double-positive cells was calculated. The data represent the mean of four in-
dependent experiments, the SD being below 10%.Weiss et al. Expression of CD44 Isoforms on Langerhans Cells 1141
meer, H. Dittmar, and J.C. Simon, unpublished results),
and v5-, v6-, or v9-specific mAbs were injected into the
dermis of skin punch biopsies (Fig. 5 A) or added to the
medium of floating split thickness keratome skin (Fig. 5, B
and C). LC remaining in the epidermis (punch biopsies) or
LC appearing in the medium (keratome skin) were
counted by microscopy and FACS®, respectively. LC were
arrested in the epidermis by two NH2-terminal–specific
antibodies (60–80% inhibition) (Fig 5, A–C) but not by v
exon–specific mAbs (Fig. 5 C). Other antibodies recogniz-
ing the NH2 terminus were also inhibitory (not shown), while
the antibody against the v7/v8 epitope was not (Fig. 5 C).
Since LC within the paracortical zones of LN were
found to express high levels of pan CD44 epitopes and
epitopes encoded by CD44v5, v6, and v9, we determined
whether these isoforms are of functional relevance for the
capacity of LC to adhere to LN. MACS-purified fresh or
48-h cultured LC were used in an LN frozen section bind-
ing assay. LC were identified by counterstaining with a
CD1a mAb and specific adherence to LN was determined
microscopically. Freshly isolated LC, like immature DC
generated from peripheral blood, showed only weak bind-
ing to lymph node cryosections (Fig. 6 A and data not
shown). By contrast, cultured LC and cytokine-activated
DC adhered specifically and at enhanced efficiency to the
paracortical T cell areas but not to the central follicular B
cell area (Fig. 6, B and C). Preincubation with the CD44v6-
specific VFF18 mAb significantly inhibited the binding of
cultivated LC (by 66%) and DC (by 49%) to the T cell
zones (Fig. 6, D and E). The MEM-85 mAb also inhibited
binding, although less efficiently. Other antibodies recog-
nizing the NH2 terminus of CD44 or mAbs directed
against other v exon epitopes or against ICAM-1, although
expressed abundantly, had no effect (Fig. 6, D and E).
CD44 Isoforms Serve a Functional Role in Antigen 
Presentation by LC
The ultimate test of LC function addresses their role in
vivo in presenting an antigen encountered in skin to T cells
Figure 2. Transmission electron microscopy of LC migrating in skin organ cultures. Skin organ cultures were performed as described in
Materials and Methods. 4-mm skin punch biopsies were cultured in Nunc filters for 12 h and examined by electron microscopy. (A) Af-
ter 12 h of culture, an LC with a multilobulated nucleus is migrating across the dermo-epidermal junction (arrow). (B) High magnifica-
tion of the same LC shown in the box in A. (Inset) Magnified from the area delineated by the box: Birbeck granules. (C) LC form cord-
like structures within dermal lymphatic vessels after 24 h of culture. (D) High magnification of an LC in lymphatic vessel identified by a
single layer of endothelial cells with protruding nuclei (arrow). (Inset) Magnified from the area delineated by the box: Birbeck granule
remnants. Bars: (A and C) 6 mm; (B and D) 0.8 mm.The Journal of Cell Biology, Volume 137, 1997 1142
within LN. This can be tested by the induction of delayed
type hypersensitivity (DTH) against an epicutaneously ap-
plied hapten. The DTH response segregates into a sensiti-
zation and a challenge phase (12). The sensitization phase
describes a set of events that occur after the first applica-
tion of a hapten to skin. Within the epidermis, the hapten
is picked up by LC, which then migrate into the regional
LN where they present the hapten to specific T cells. Dur-
Figure 3. CD44 expression pattern on LC migrating
from epidermis into dermis. Cryosections of skin
cultured for 12 h were stained with Lag mAb fol-
lowed by secondary FITC-conjugated F(ab), goat
anti–mouse IgG (H1L) to detect LC (green), and
CD44 mAbs followed by a Cy3-conjugated goat
F(ab)2 anti–mouse IgG (H1L) antibody (red). Dou-
ble-positive cells appear yellow-orange. (A) Staining
with Lag and anti–pan CD44. Lag1 cells within the
epidermis (1) and those that migrated into the der-
mis (2) stained double positive for Lag and pan
CD44 (yellow). Keratinocytes express pan CD44 but
not Lag (red). Lag1 intra-epidermal LC also ex-
press the epitope created by exons v7/v8 (B) but
very low levels of CD44 exon v5 (C), v6 (E), and v9
(G) epitopes. Lag1 cells that migrated into dermis
express CD44v5 (D), v6 (F), and v9 (H). (I and J)
LC that had migrated from split thickness skin were
gated for CD1a expression, stained with the mAbs
indicated, and analyzed by FACS® as in Fig. 1. Bar,
10 mm.Weiss et al. Expression of CD44 Isoforms on Langerhans Cells 1143
ing the challenge phase, the same hapten is reapplied and
induces a local inflammatory response, which is dependent
on leukocyte extravasation into the application site, but
does not require LC (4, 13). To test the function of CD44
epitopes in DTH, mice were sensitized epicutaneously to
the hapten DNFB on days 0 and 1, which upon challenge
with the same hapten to ear skin at day 6 results in a mas-
sive DTH reaction measured by ear swelling, peaking at 24 h
after challenge and declining during the next 72 h (Fig. 7,
Group 1; Fig. 8 B). Anti-CD44 mAbs were injected i.p. at
days 21, 0, and 11 with respect to hapten application (to
test for interference with the sensitization phase of DTH)
or at days 5, 6, and 7 (to test for an interference with the
challenge phase). Antibodies to the NH2 terminus of
CD44 and to the v6 epitope inhibited the challenge phase
of DTH resulting in a delayed onset of DTH as reported
for the pan CD44 mAb previously (8) (Fig. 7, Group 3).
Most importantly, only the CD44v4 and v6, but not pan
CD44 or control mAbs, inhibited markedly the sensitiza-
tion phase requiring LC migration from epidermis to
lymph nodes and hapten presentation (Fig. 7, Group 2).
Furthermore, injection of anti-v6 and -v4 mAbs during
sensitization or challenge did not delay the onset of DTH.
These findings were confirmed and extended by histologi-
cal examination of the challenge sites (Fig. 8). When in-
jected during the sensitization phase, only anti-v4 and -v6
mAbs reduced tissue oedema and the influx of leukocytes
into the dermis, while pan CD44 or control mAb had no
effect (Fig. 8, B and D–F). When injected during the chal-
lenge, pan CD44 and anti-v6 mAb delayed the influx of
leukocytes into the dermis, anti-v4 and IgG control mAb
did not affect the DTH response significantly. These data
suggest that CD44 splice variant expression is of key im-
portance for the capacity of LC to induce a DTH response
Figure 4. CD44 expression on LC that have homed to LN. Cryosections of axillary LN were stained as described above. (A) Pan CD44
staining of Lag1 cells (yellow) located in the paracortical T cell areas of axillary lymph nodes draining the skin. T cells also express
CD44 but no Lag (red). (B) Lag-positive cells express exon v5 epitope. (C) Exon v9 epitope is expressed on the majority (yellow) but
not all (arrow, green) LC. Bar, 10 mm.
Figure 5. Antibodies to the CD44 NH2 terminus prevent LC acti-
vation and migration. (A) Photomicrograph of punch biopsies in-
jected with IgG1 control or mAb MEM-85. CD1a-positive LC are
labeled green. The dotted line indicates the dermo–epidermal
junction. Arrow indicates a cord of emigrated LC within dermis.
(B) Addition of MEM-85 or control mAb to split thickness skin
cultures. The cells that had migrated out of split thickness skin
into the medium were analyzed by FACS®. CD1a1, viable (PI-
negative) LC are circled. The fraction of these cells over total cell
number is shown as percentage in the upper left corner of each
graph. The CD1a2 keratinocytes were forced into suspension by
dermatome manipulation. (C) Inhibition of LC emigration into
the medium by various anti-CD44 antibodies. Percent inhibition
was calculated from five independent experiments (6SD; *statis-
tically significant at P , 0.05, one way analysis of variance
(ANOVA), Dunnett’s test, SigmaStat; Jandel Scientific Software,
Corte Madern, CA).The Journal of Cell Biology, Volume 137, 1997 1144
against epicutaneously applied haptens. During this sensi-
tization phase, CD44 variants may play an essential role
either during LC migration to LN or during their interac-
tion with T cells. During the challenge phase, CD44 NH2-
terminal and v6 epitopes appear to be required for leuko-
cyte extravasation into the site of hapten challenge.
Discussion
In this study we demonstrate that LC and DC during in
vitro activation and during their in vivo migration to the
peripheral LN differentially upregulate pan CD44 epitopes
and sequences encoded by variant exons CD44v4, v5, v6,
and v9. Thus LC and DC activation or migration is accom-
panied by increased synthesis of CD44 and by a change of
either epitope accessibility or splicing. The mechanisms
underlying this change remain to be elucidated: granulo-
cyte macrophage colony stimulating factor (GM-CSF), tu-
mor necrosis factor-a, and interleukin-1b, secreted by ke-
ratinocytes in response to antigen application to the skin,
play a role in LC-maturation, emigration, and accumula-
tion in LN (9, 11, 16). Furthermore, the generation of acti-
vated DC from peripheral blood precursors depends upon
the presence of GM-CSF (35). However, at present we
have no evidence that GM-CSF and tumor necrosis factor-
a are involved in CD44 modulation by LC or DC, since bi-
ologically active mAbs neutralizing these cytokines added
during culture had no effect (not shown). Another possi-
bility is that the change in CD44 isoform expression occurs
when LC or DC encounter new ECM components during
their migration to the lymph node. In fact, in skin explants
we only observed upregulation of CD44 variant exon se-
quences after LC had penetrated the basement membrane
of the epidermo–dermal junction.
We have shown that LC emigration from the epidermis
is inhibited by mAbs against the NH2 terminus of CD44.
In contrast, mAb directed against CD44 variant epitopes
encoded by exons v5, v6, v7/8, or v9 had no effect. These
Figure 6. The binding of LC or DC to paracortical lymph node areas is inhibited by antibodies to CD44. Microbead-purified fresh LC
(A), LC cultivated for 48 h (B and E), or cytokine-activated DC (C, D, and F) were layered on frozen sections of lymph node. LC and
DC adhered preferentially to the paracortical T cell areas, with enhanced adhesion upon activation by culture, and not to the central B
cell follicles. The binding was also assayed in the presence of antibodies (quantified in E and F; *statistically significant at P , 0.05, one
way ANOVA, Dunnett’s test). Representative for four independent experiments. Bar: (A–C) 10 mm; (D) 100 mm.
Figure 7. Antibodies to CD44v epitopes inhibit the sensitization phase of contact hypersensitivity in vivo. Group 2 mice were treated
with mAbs i.p. as indicated both before and during sensitization, and group 3 mice were treated similarly before and during challenge.
Mice in group 1 were not treated with mAbs. *Statistically significant reduction of ear swelling at P , 0.05 (one way ANOVA, Dun-
nett’s test). Each bar represents mean ear swelling data pooled from eight animals measured 24, 48, and 72 h after challenge.Weiss et al. Expression of CD44 Isoforms on Langerhans Cells 1145
results suggest that CD44 epitopes within the NH2 termi-
nus of CD44 are involved in a very early stage of intraepi-
dermal LC activation required for their emigration out of
skin. Once LC are activated and express epitopes encoded
by CD44 variant exons, antibodies recognizing pan CD44
epitopes cannot interfere with their emigration. At present,
we can only speculate on the mechanisms by which pan
CD44 mAb inhibits LC migration. CD44 is the major
ligand for HA (2, 46), and LC emigration could be par-
tially inhibited by mAb MEM-85, which is known to block
CD44–HA interactions (6). We hypothesize that upregula-
tion of CD44 epitopes involved in HA binding could facili-
tate LC movement along HA structures within the dermis.
However, mAbs SFF-2 and BU52, which do not affect HA
binding, also blocked, raising the possibility that these
mAbs interfere with the binding of other CD44 ligands in-
volved in cell migration such as osteopontin (50), bFGF,
MIP-1b (5, 47), or the N-linked blood group Ag (27).
These mAbs may also alter the clustering of CD44 on the
cell surface, thereby disturbing formation and stabilization
of the cell–ECM attachments essential for migration (28).
Expression of distinct CD44 isoforms is also of func-
tional relevance for the homing of lymphocytes or tumor
cells to lymphatic tissues (15). Monoclonal Abs against
pan CD44 epitopes interfere with the homing of nontrans-
formed lymphocytes or lymphoma cells to peripheral
lymph nodes (22, 33, 52). CD44 isoforms containing v6
epitopes are required for the initial phase of lymphogenic
spread of rat pancreatic adenocarcinoma cell lines (14, 38).
In humans, a high potential for lymphogenic metastasis of
non-Hodgkin lymphomas has been linked to expression of
CD44v6 exon sequences (25, 44). Here we demonstrate
that the ability of LC and DC to home to peripheral LN is
related to the expression of CD44 variant exon v6 encoded
isoforms. Specifically, LC freshly isolated from skin and
immature DC from peripheral blood, which do not express
CD44v exon–encoded sequences, showed low specific
binding to LN. In contrast, after upregulation of CD44v
exon–containing isoforms, cultured LC or DC strongly ad-
hered to the marginal sinus and the paracortical T cell ar-
eas but not to the central B cell follicle or the LN medulla.
Preincubation with CD44v6-specific mAb significantly in-
hibited this binding to the T cell zones. The pan CD44
mAb MEM-85 also inhibited binding, although less effi-
ciently, while other antibodies recognizing the NH2 termi-
nus of CD44, or directed against other v exon epitopes or
ICAM-1, had no effect. The data with the anti-v6 mAbs
suggest that CD44 mediates the binding of LC and DC to
an unidentified partner in the T cell zone of lymph nodes.
The effect of MEM-85 may indicate a role of binding to HA
(which is presumably not confined to T cell zones) or more
likely to the same partner affected by the anti-v6 mAb.
We have shown that LC use a differential modulation of
CD44 isoforms for adhesion to T cell zones in LN, suggest-
ing that such modulation is of central importance for their
ability to induce primary T cell responses within that LN.
We also show that CD44 isoform expression by LC is of
relevance for their capacity to induce a DTH response to
epicutaneously applied hapten. We found that v4- and v6-
specific antibodies strongly inhibited sensitization, which
is dependent upon LC migration and LN homing. The in-
terference of anti-CD44v6 antibodies with LC function
may partly explain their effect on primary immune re-
sponses (1, 31). We conclude that CD44 variants play an
essential role in LC function, either during migration to
the lymph nodes or in the interaction with T cells during
sensitization. In contrast, antibodies to the NH2 terminus
of CD44 and to the v6 epitope delayed the extravasation
phase of DTH. Inhibition by NH2-terminal CD44 antibod-
ies of the extravasation phase of DTH has been reported
earlier (8). The inability of NH2-terminal–specific anti-
CD44 antibodies to inhibit LC activation in the epidermis
during the sensitization phase as they can in vitro is proba-
bly either due to basement membrane barriers that pre-
Figure 8. Histology of DTH
ear swelling response follow-
ing anti-CD44 mAb injection.
Mouse ears were excised 24 h
after DNFB challenge, fixed
in formaldehyde, embedded
in paraffin, sectioned, and
stained with hematoxylin and
eosin. Mice were treated as
follows: (A) unsensitized, (B)
IgG control mAb injection
during sensitization, (C) IgG
control mAb injection during
ear challenge, (D) panCD44
mAb injection during sensiti-
zation, (E) CD44v4 mAb in-
jection during sensitization,
(F) CD44v6 mAb injection
during sensitization, (G) pan
CD44 mAb injection during
challenge, (H) anti-CD44v4
mAb injection during chal-
lenge, and (I) anti-CD44v6
mAb injection during chal-
lenge. Bar, 50 mm.The Journal of Cell Biology, Volume 137, 1997 1146
vent efficient entry of antibody into the epidermis after
systemic application (8) or due to functional differences of
the CD44 mAbs used in the in vitro and in vivo assays.
In conclusion, we have demonstrated that during in vitro
activation as well as during their migration to peripheral
lymph nodes, LC and DC upregulate pan CD44 epitopes
and sequences encoded by CD44 variant exons. These
CD44 proteins play an essential role in LC and DC func-
tion since mAbs against different CD44 epitopes inhibit
the migration of LC out of skin, the adhesion of LC and
DC to LN T cell areas and the capacity of LC to initiate a
DTH response to epicutaneously applied hapten. The in-
teresting parallel of LC and DC behavior with the lym-
phatic spread of metastasizing tumor cells and the inhibi-
tion of both by anti-CD44v6 antibodies strongly suggests a
similar role for CD44 in both processes. We propose that
selection for and mimicry of the molecular function of
CD44 on LC and DC occurs during tumor progression.
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